Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Complement Integr Med ; 17(1)2019 Dec 21.
Article in English | MEDLINE | ID: mdl-31865288

ABSTRACT

Background This study was designed to examine the effectiveness of program combining chakrayoga and meditation on the physical health and disease-related factors and psychological factors of people. Methods Ninety-seven subjects (32-83 years old) who had free from prior experiences in meditation programs or Chakrayoga training courses were assigned to either the experimental group (EXP) (45 subjects; 13 male subjects and 32 female subjects; average age of 60.67 years, SD=11.09 years) or the control group (CONT) of remaining subjects (52 subjects; 14 male subjects and 38 female subjects; average age of 61.58 years, SD=9.70 years). Subjects in the EXP participated in the Chakrayoga Meditation Program for twice a week for 2 h during 6 weeks in each session consisted of 1 h of Chakrayoga and 1 h of meditation. The measurements in this study included the mindfulness, stress response, subjective quality of life, medical symptom checklist, difficulty in emotional regulation and objective of life and sense of control. Results Results revealed that participants in the EXP reported significantly more relief of mindfulness, stress response, subjective quality of life and medical symptom checklist than those in the CONT. Conclusions These findings provide evidence that the Chakrayoga Meditation Program can help relieve the physical health and disease-related factors and psychological factors.


Subject(s)
Behavioral Symptoms/therapy , Meditation/methods , Yoga , Adult , Aged , Aged, 80 and over , Anger , Depression , Emotions , Female , Humans , Male , Middle Aged , Mindfulness , Quality of Life , Stress, Psychological , Surveys and Questionnaires
2.
J Vet Sci ; 20(3): e30, 2019 May.
Article in English | MEDLINE | ID: mdl-31161748

ABSTRACT

Gonadotropin-releasing hormone (GnRH) is secreted from the hypothalamus and anti-GnRH antibodies are not formed under normal conditions. However, administration an excess of recombinant GnRH protein results in the formation of anti-GnRH. We evaluated the efficacy of the recombinant Salmonella typhimurium flagellin fljB (STF2)-GnRH vaccine in inducing infertility in 17 intact male cats. The first vaccination and a boosting vaccine was injected for examination. Serum was obtained from blood collected at monthly intervals and anti-GnRH antibodies and testosterone concentrations were determined. Six months after the vaccination, testicular samples are obtained and used for histological examination. Compared with sham control group, the injection groups showed an increase in anti-GnRH antibody titers and testosterone concentrations tended to be reduced in the injection groups and increased in the control group. Histological evaluations and Johnsen's testicular biopsy scores revealed testicular hypoplasia in the 2 injection groups. Consequently, normal sexual maturation with sperm production was observed in the control group. In contrast, the cats that received the GnRH vaccine showed weak (2 of 7 cats) or moderate (4 out of 7 cats) dose-dependent infertility effects. On the basis of the results, the STF2-GnRH vaccine was identified to be effective in inducing infertility in male cats. The results of this study thus indicate the possibility of immunological castration targeting feral cats.


Subject(s)
Flagellin/immunology , Gonadotropin-Releasing Hormone/immunology , Infertility, Male/chemically induced , Orchiectomy/veterinary , Sexual Maturation/drug effects , Spermatogenesis/drug effects , Vaccines, Contraceptive/standards , Animals , Antibodies/blood , Cats , Escherichia coli/genetics , Flagellin/genetics , Gonadotropin-Releasing Hormone/genetics , Male , Orchiectomy/methods , Recombinant Proteins/pharmacology , Testis/drug effects , Testosterone/blood , Vaccines, Contraceptive/pharmacology , Vaccines, Synthetic/immunology , Vaccines, Synthetic/pharmacology
3.
J Pediatr Surg ; 51(7): 1192-6, 2016 Jul.
Article in English | MEDLINE | ID: mdl-26976774

ABSTRACT

PURPOSE: To evaluate protective effect of pterostilbene against testicular ischemia/reperfusion (I/R) injury, which results in increased formation of oxidative stress, leading to testicular apoptosis and impaired spermatogenesis. METHODS: Thirty two pubertal male Sprague-Dawley rats weighing 180-220g were selected and randomly divided into the following four groups: group A (normal control group), group B (sham-operated group), group C (induced I/R injury group), group D (induced I/R injury group receiving pterostilbene treatment). Johnsen's scores and mean seminiferous tubule diameters were evaluated for histopathologic assessment; germinal cell apoptosis was evaluated by the transferase dUTP nick end labeling (TUNEL) assay and immunohistochemistry for caspases. Malondialdehyde (MDA) levels were assessed as an indicator of oxidative stress and total antioxidant capacity (TAC) was measured. RESULTS: Germ cell apoptosis and MDA level significantly increased whereas TAC significantly decreased in group C; moreover, abnormal morphology and impaired spermatogenesis were observed in group C. In contrast, treatment with pterostilbene inhibited lipid peroxidation and apoptosis induced by ROS and restored the antioxidant capacity in group D. CONCLUSIONS: These results show that treatment with pterostilbene may be a promising therapy for testicular I/R injury.


Subject(s)
Antioxidants/therapeutic use , Reperfusion Injury/prevention & control , Spermatic Cord Torsion/complications , Stilbenes/therapeutic use , Animals , Antioxidants/pharmacology , Apoptosis/drug effects , Biomarkers/metabolism , Lipid Peroxidation/drug effects , Male , Malondialdehyde/metabolism , Oxidative Stress/drug effects , Random Allocation , Rats , Rats, Sprague-Dawley , Reperfusion Injury/metabolism , Reperfusion Injury/pathology , Spermatic Cord Torsion/metabolism , Spermatic Cord Torsion/pathology , Stilbenes/pharmacology , Testis/drug effects , Testis/metabolism , Testis/pathology , Treatment Outcome
4.
J Am Assoc Lab Anim Sci ; 51(2): 246-52, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22776126

ABSTRACT

This study used positron emission tomography-computed tomography (PET-CT) to evaluate the effects of 4 anesthetic protocols on 2-deoxy-2-[18F]-fluoro-D-glucose (18F-FDG) accumulation in the brains and hearts of miniature pigs (Sus scrofa domestica). The 18F-FDG standard uptake value was quantified by dividing the brain into 6 regions: cerebellum, brainstem, and frontal, parietal, temporal, and occipital lobes. Five (2 female and 3 male) clinically normal miniature pigs were premedicated with medetomidine (200 µg/kg IM) after which the following 4 anesthetic protocols were administered by using a crossover design: 1) propofol (4 mg/kg IV)-isoflurane inhalation; 2) propofol (4 mg/kg IV); 3) ketamine (5 mg/kg IV); 4) tiletamine-zolazepam (4.4 mg/kg IM). Compared with levels after other protocols, brain accumulation of 18F-FDG increased during propofol anesthesia but decreased with tiletamine-zolazepam. Relative to that due to other protocols, heart accumulation of 18F-FDG increased with propofol-isoflurane anesthesia but decreased with tiletamine-zolazepam. Comparing glucose accumulation in the brain and heart of miniature pigs by using PET-CT, we found that glucose accumulation varied according to the anesthetic protocol and between the 2 organs. These results can be used to evaluate how different anesthetic agents affect glucose metabolism in brain and heart of miniature pigs. Furthermore, these data should be considered when selecting an anesthetic agent for miniature pigs that will undergo PET-CT imaging with 18F-FDG.


Subject(s)
Anesthetics, Combined/administration & dosage , Brain/metabolism , Fluorodeoxyglucose F18/pharmacokinetics , Myocardium/metabolism , Radiopharmaceuticals/pharmacokinetics , Swine, Miniature/metabolism , Anesthetics, Dissociative/administration & dosage , Anesthetics, Inhalation/administration & dosage , Anesthetics, Intravenous/administration & dosage , Animals , Anti-Anxiety Agents/administration & dosage , Brain/diagnostic imaging , Cross-Over Studies , Drug Combinations , Female , Fluorodeoxyglucose F18/administration & dosage , Heart/diagnostic imaging , Isoflurane/administration & dosage , Ketamine/administration & dosage , Male , Multimodal Imaging/veterinary , Positron-Emission Tomography , Propofol/administration & dosage , Radiopharmaceuticals/administration & dosage , Swine , Tiletamine/administration & dosage , Tomography, X-Ray Computed , Zolazepam/administration & dosage
5.
Behav Brain Res ; 233(2): 434-42, 2012 Aug 01.
Article in English | MEDLINE | ID: mdl-22659394

ABSTRACT

Zoletil(®) is a 1:1 combination of the N-methyl-d-aspartate (NMDA) receptor antagonist, tiletamine, and the benzodiazepine, zolazepam, commonly used as a veterinary anesthetic. There have been previous reports on the abuse of zoletil in humans, and these motivated us to investigate the rewarding and reinforcing effects of the drug. We experimented whether zoletil and its constituents, tiletamine and zolazepam, produces place preference and/or facilitates self-administration. Then we compared the effects of zoletil to that of the recreationally abused veterinary anesthetic, ketamine. We also delved into the consequences of drug pre-exposure, thus parallel experiments were performed on rats pre-treated with the drug for 14 days. Our findings indicated that zoletil produced neither reward nor reinforcement in drug-naïve rats; however, repeated pre-treatment of zoletil produced significant place preference and self-administration. Tiletamine generated both place preference and self-administration; while zolazepam induced place preference but was not self-administered, even in pre-treated animals. The rewarding and reinforcing effects produced by zoletil were comparable to that of ketamine. Therefore, zoletil per se, has no motivational effects but the changes in neuronal functions and behavior consequential to repeated zoletil treatment may contribute in part to the addiction liability of the drug. Furthermore, the present study suggests that complex interactions occur with acute or repeated treatment of an NMDA receptor antagonist-benzodiazepine combination.


Subject(s)
Anesthetics/pharmacology , Conditioning, Operant/drug effects , Reinforcement, Psychology , Reward , Tiletamine/pharmacology , Zolazepam/pharmacology , Analysis of Variance , Animals , Anti-Anxiety Agents/pharmacology , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Combinations , Ketamine/pharmacology , Male , Rats , Rats, Sprague-Dawley , Self Administration , Time Factors
6.
J Pediatr Surg ; 47(4): 736-42, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22498389

ABSTRACT

PURPOSE: This study evaluated whether 2% hydrogen (H(2)) gas therapy protects against testicular ischemia/reperfusion injury which results in increased formation of reactive oxygen species and/or reactive nitrogen species, leading to testicular apoptosis and impaired spermatogenesis. METHODS: Pubertal six-week-old Spraque-Dawley rats were assigned to 5 groups (10 animals/group) as follows: group A was a sham operated group; groups B, C, D, and E underwent 5 hours of left testicular ischemia followed by 0, 30, 60, and 120 minutes of 2% H(2) gas therapy, respectively. Histological analysis was performed to verify structure and morphology of the testes and to investigate Johnsen scores, mean seminiferous tubule diameter, and the number of germ cell layers to classify spermatogenesis. Germ cell apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling assay and Bax/Bcl-2 ratio real-time polymerase chain reaction. We also investigated malondialdehyde levels as an indicator of lipid peroxidation. RESULTS: Compared to the sham group (A), germ cell apoptosis and lipid peroxidation in the ischemia group (B) were significantly increased with abnormal morphology and impaired spermatogenesis. In contrast, amelioration of testicular damages was evident in the H(2) therapy groups (C, D, and E). CONCLUSIONS: Our results showed that inhalation of 2% H(2) gas may be a promising therapy with anti-apoptotic and anti-oxidant properties in cases of testicular ischemia/reperfusion injury.


Subject(s)
Antioxidants/therapeutic use , Hydrogen/therapeutic use , Reperfusion Injury/prevention & control , Spermatic Cord Torsion/complications , Administration, Inhalation , Animals , Antioxidants/pharmacology , Apoptosis/drug effects , Biomarkers/metabolism , Disease Models, Animal , Hydrogen/pharmacology , Lipid Peroxidation/drug effects , Male , Malondialdehyde/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Random Allocation , Rats , Rats, Sprague-Dawley , Reperfusion Injury/etiology , Reperfusion Injury/metabolism , Spermatogenesis/drug effects , Treatment Outcome , bcl-2-Associated X Protein/metabolism
7.
Lab Anim Res ; 27(3): 197-203, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21998608

ABSTRACT

Tribromoethanol (2,2,2-tribromoethanol, TBE) is a popular injectable anesthetic agent used in mice in Korea. Our goal was to assess the risks associated with side effects (lesions) in the abdominal cavity, especially at high doses. To understand the underlying pathophysiological changes, we examined levels of cytokines through ELISA of abdominal lavage fluid and spleen collected from mice treated with low and high-dose TBE. ICR mice were anesthetized using one of the following protocols: a combination of TBE 200 mg/kg (1.25%) and xylazine 10 mg/kg; TBE 400 mg/kg (1.25%); and TBE 400 mg/kg (2.5%). Administration of high-dose TBE (400 mg/kg) increased the interleukin-1ß and interleukin-6 levels in the peritoneal cavity over the short term (<1 day) compared with sham controls and low-dose TBE (200 mg/kg) groups. Cytokine expression in the low-dose TBE group was similar to the control group, whereas in the high-dose TBE group cytokine levels were higher in abdominal lavage fluid and spleen over the long term (10 days post-injection). We conclude that a combination of TBE 200 mg/kg (1.25%) and xylazine (10 mg/kg) is a safe and effective anesthetic for use in animals.

SELECTION OF CITATIONS
SEARCH DETAIL